Notice of AGM
Genflow Biosciences Plc has announced its Annual General Meeting will be held on June 29, 2026, with the Notice and Form of Proxy to be available on its website. The company also reported that its Annual Report and Accounts for the year ended December 31, 2025, are now accessible. In a board change, Independent Non-Executive Director Peter King-Lewis is stepping down with immediate effect, and the company expressed gratitude for his contributions since the IPO.
Select text to share a quote on X · sign in to keep highlights & notes in your GENF notes
Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that it will hold its Annual General Meeting ("AGM") at 11am on Monday 29 June 2026 at One Heddon Street, London, W1B 4BD.
The Notice of the AGM ("Notice") and Form of Proxy will shortly be available on the Company's website, www.genflowbio.com, and have, where applicable, been posted to shareholders. Further details of the arrangements for this year's AGM are set out in the Notice.
As announced on 30 April 2026, the Company's Annual Report and Accounts for the year ended 31 December 2025 are also available on the website and have, where applicable, also been posted to shareholders.
Board changes
The Company also announces that Peter King-Lewis, an Independent Non-Executive Director, is stepping down from the Board with immediate effect.
The Board would like to sincerely thank Peter for his valuable contribution to the Company during his tenure as a Director. His commitment and unwavering support has been instrumental in helping guide the Company from its IPO through to its current stage of development.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.